Header

For Healthcare Professionals

Global website Opens in new tab

Contact us Opens in new tab

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Home
Therapeutic Areas
Therapeutic Areas

We combat interconnected cardio-renal-metabolic issues that cause 20 million deaths annually as part of our efforts to address global health threats. Innovative, comprehensive treatments are given priority in our R&D.

Read more

Therapeutic Areas

Read more

Chronic Kidney Disease

Heart Failure
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products

Read more

Products

Read more

Glyxambi

Jardiance

Jardiance Met

Trajenta®
Patient support
Patient support

Innovation at Boehringer Ingelheim is driven by patients. Our commitment lies in investigating unaddressed needs and providing revolutionary treatments for upcoming generations.

Read more Opens in new tab

Patient support

Read more

Fact Clinic Opens in new tab
Patient care
Patient care

Patient care

A to Z of Diabetes

Chronic Kidney Disease
Articles
Double Check Campaign
Global website Opens in new tab
Contact us Opens in new tab

Boehringer Ingelheim

India: Therapeutic Areas

Boehringer
Ingelheim for Indian
Healthcare
Professionals

Your partner in daily practice and patient consultation

Therapeutic Areas

Discover the facts

CKD

Chronic Kidney Disease

Discover the facts

Discover the facts

Heart Failure

Heart Failure

Discover the facts

Home
Therapeutic Areas

Contact Us Opens in new tab
Privacy Policy Opens in new tab
Sitemap
Terms of Use Opens in new tab

Therapeutic Area

This information is for use of Indian Healthcare Professionals only. Products discussed herein may have different labeling in different countries.
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Notice.

Copyright © 2025 Boehringer Ingelheim India Private Limited. All rights reserved. SC-IN-01592 valid till December 2027, Last review date: 02/12/2025